Kantsevoy SV, Mercy Medical Center Baltimore MD, USA

The latest news about Lumendi

A Randomized Prospective Study Evaluating Effectiveness Of A Double Balloon Endolumenal Platform For Colorectal EndoscopicSubmucosal Dissection

Endoscopic removal of colonic polyps and early cancers eliminates the need for surgical resection and possible temporary or permanent colostomy.

Lumendi Receives 510(k) Clearance for Two New Devices

Company Achieves New Milestone with Over 4,000 Therapeutic Procedures Completed Across the U.S., Europe and Asia, Using DiLumen™ Endoluminal Interventional Platform February 16, 2023 08:00 AM Eastern Standard Time WESTPORT,… Continue reading Lumendi Receives 510(k) Clearance for Two New Devices

Lumendi receives 510k clearance for two new devices

Company Achieves New Milestone with Over 4,000 Therapeutic Procedures Completed Across the U.S., Europe and Asia, Using DiLumen™ Endoluminal Interventional Platform February 16, 2023 08:00 AM Eastern Standard Time WESTPORT,… Continue reading Lumendi receives 510k clearance for two new devices

30% of surgical interventions are unnesessary

Dr. Peter Johann, CEO & Founder of Lumendi and Prof. Bauerfeind discussed how treatment methods such as EMR and ESD can be made more accessible to patients. Prof. Bauerfeind: "Sometimes these treatments… Continue reading 30% of surgical interventions are unnesessary

Introducing EZ Glide in Europe

Many studies have documented that an endoscopic approach for ESD is a safer and less expensive alternative to removing these polyps, leading to fewer postoperative complications and shorter hospital stays.